Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy.
暂无分享,去创建一个
[1] J. Jakubowski,et al. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation , 2011, Journal of thrombosis and haemostasis : JTH.
[2] Scott R Kegler,et al. National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin. , 2010, Archives of internal medicine.
[3] S. Yusuf,et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial , 2010, The Lancet.
[4] O. Boutaud,et al. PGE2 decreases reactivity of human platelets by activating EP2 and EP4. , 2010, Thrombosis research.
[5] J. Mitchell,et al. Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy , 2010, Journal of thrombosis and haemostasis : JTH.
[6] I. Graham,et al. Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. , 2009, Journal of the American College of Cardiology.
[7] J. Mitchell,et al. Utility of 96-well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectiveness , 2009, Thrombosis and Haemostasis.
[8] Claes Held,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.
[9] M. Cattaneo,et al. New P2Y12 blockers , 2009, Journal of thrombosis and haemostasis : JTH.
[10] Ming-Zhi Zhang,et al. Faculty Opinions recommendation of Prostaglandin F2alpha elevates blood pressure and promotes atherosclerosis. , 2009 .
[11] R. Collins,et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009, The Lancet.
[12] C. Patrono,et al. Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges. , 2009, Molecular interventions.
[13] N. Curzen,et al. Effects of clopidogrel on “aspirin specific” pathways of platelet inhibition , 2009, Platelets.
[14] G. Lemesle,et al. Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. , 2008, The American journal of cardiology.
[15] Sunil V. Rao,et al. Antiplatelet Therapy Use After Discharge Among Acute Myocardial Infarction Patients With In-Hospital Bleeding , 2008, Circulation.
[16] G. Baldanzi,et al. The Gi-coupled P2Y12 Receptor Regulates Diacylglycerol-mediated Signaling in Human Platelets* , 2008, Journal of Biological Chemistry.
[17] D. Glavač,et al. Cyclooxygenase in normal human tissues – is COX-1 really a constitutive isoform, and COX-2 an inducible isoform? , 2008, Journal of cellular and molecular medicine.
[18] J. Hirsh,et al. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[19] P. McGettigan,et al. Selective COX-2 inhibitors, NSAIDs and congestive heart failure: differences between new and recurrent cases. , 2008, British journal of clinical pharmacology.
[20] J. Stallone,et al. Sympathy for the devil: the role of thromboxane in the regulation of vascular tone and blood pressure. , 2008, American journal of physiology. Heart and circulatory physiology.
[21] E. Rimm,et al. Acceleration of Cardiovascular Disease by a Dysfunctional Prostacyclin Receptor Mutation: Potential Implications for Cyclooxygenase-2 Inhibition , 2008, Circulation research.
[22] M. Keltai,et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial , 2008, The Lancet.
[23] C. Hennekens,et al. Cyclooxygenase-2 Inhibitors and Most Traditional Nonsteroidal Anti-inflammatory Drugs Cause Similar Moderately Increased Risks of Cardiovascular Disease , 2008, Journal of cardiovascular pharmacology and therapeutics.
[24] C. Gachet. P2 receptors, platelet function and pharmacological implications , 2008, Thrombosis and Haemostasis.
[25] J. Mitchell,et al. COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs , 2008, The Lancet.
[26] Andrew J. Johnson,et al. DG-041 inhibits the EP3 prostanoid receptor—A new target for inhibition of platelet function in atherothrombotic disease , 2008, Platelets.
[27] L. Wallentin,et al. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. , 2007, Cardiovascular drug reviews.
[28] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[29] Yuan-sheng Gao,et al. Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting. , 2007, The Journal of clinical investigation.
[30] G. FitzGerald. COX-2 in play at the AHA and the FDA. , 2007, Trends in pharmacological sciences.
[31] Susan Smyth,et al. Aspirin dose for the prevention of cardiovascular disease: a systematic review. , 2007, JAMA.
[32] S. Narumiya,et al. Prostaglandin E Receptors* , 2007, Journal of Biological Chemistry.
[33] E. Antman,et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. , 2007, Circulation.
[34] M. Cattaneo,et al. Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin , 2007, Journal of thrombosis and haemostasis : JTH.
[35] N. Kleiman,et al. Reticulated platelets and uninhibited COX‐1 and COX‐2 decrease the antiplatelet effects of aspirin , 2007, Journal of thrombosis and haemostasis : JTH.
[36] W. White. Cardiovascular effects of the cyclooxygenase inhibitors. , 2007, Hypertension.
[37] N. Flavahan. Balancing prostanoid activity in the human vascular system. , 2007, Trends in pharmacological sciences.
[38] E. Rimm,et al. Frequency of analgesic use and risk of hypertension among men. , 2007, Archives of internal medicine.
[39] J. Vonesch,et al. Vascular wall–produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors , 2007, The Journal of experimental medicine.
[40] M. Cattaneo. Platelet P2 receptors: old and new targets for antithrombotic drugs , 2007, Expert review of cardiovascular therapy.
[41] S. Kunapuli,et al. Nucleotide receptor signaling in platelets , 2006, Journal of thrombosis and haemostasis : JTH.
[42] E. Antman,et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). , 2006, American heart journal.
[43] J. Hallas,et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study , 2006, BMJ : British Medical Journal.
[44] M. Cattaneo. ADP receptors: inhibitory strategies for antiplatelet therapy. , 2006, Timely topics in medicine. Cardiovascular diseases.
[45] J. Emberson,et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials , 2006, BMJ : British Medical Journal.
[46] Á. Lanas,et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations , 2006, Gut.
[47] Ying Yu,et al. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. , 2006, The Journal of clinical investigation.
[48] A. Sacchetti,et al. De Novo Synthesis of Cyclooxygenase-1 Counteracts the Suppression of Platelet Thromboxane Biosynthesis by Aspirin , 2006, Circulation research.
[49] C. Gachet. Regulation of platelet functions by P2 receptors. , 2006, Annual review of pharmacology and toxicology.
[50] Garret A FitzGerald,et al. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. , 2005, The Journal of clinical investigation.
[51] Colin Baigent,et al. Low-dose aspirin for the prevention of atherothrombosis. , 2005, The New England journal of medicine.
[52] C. Gachet. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. , 2005, Pharmacology & therapeutics.
[53] J. Morrow,et al. Contribution of Cyclooxygenase-2 to Elevated Biosynthesis of Thromboxane A2 and Prostacyclin in Cigarette Smokers , 2005, Circulation.
[54] R. D. Rudic,et al. COX-2–Derived Prostacyclin Modulates Vascular Remodeling , 2005, Circulation research.
[55] M. Flattery,et al. COX-2 inhibitors and cardiovascular risk. , 2005, Progress in cardiovascular nursing.
[56] E. Puré,et al. Cyclooxygenases, Thromboxane, and Atherosclerosis: Plaque Destabilization by Cyclooxygenase-2 Inhibition Combined With Thromboxane Receptor Antagonism , 2005, Circulation.
[57] M. Cattaneo. Aspirin and Clopidogrel: Efficacy, Safety, and the Issue of Drug Resistance , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[58] G. FitzGerald. Coxibs and cardiovascular disease. , 2004, The New England journal of medicine.
[59] S. Narumiya,et al. Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice , 2004 .
[60] J. Mitchell,et al. Cyclooxygenases 1, 2, and 3 and the Production of Prostaglandin I2: Investigating the Activities of Acetaminophen and Cyclooxygenase-2-Selective Inhibitors in Rat Tissues , 2004, Journal of Pharmacology and Experimental Therapeutics.
[61] J. Mitchell,et al. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[62] S. Yusuf,et al. Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes: Observations From the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study , 2003, Circulation.
[63] Xiaoping Du,et al. Two Waves of Platelet Secretion Induced by Thromboxane A2 Receptor and a Critical Role for Phosphoinositide 3-Kinases* , 2003, Journal of Biological Chemistry.
[64] R. Flower. The development of COX2 inhibitors , 2003, Nature Reviews Drug Discovery.
[65] V. Hasselblad,et al. Seeking the optimal aspirin dose in acute coronary syndromes. , 2002, The American journal of cardiology.
[66] A. Whelton. COX-2-specific inhibitors and the kidney: effect on hypertension and oedema. , 2002, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.
[67] I. Song,et al. The enzymology of prostaglandin endoperoxide H synthases-1 and -2. , 2002, Prostaglandins & other lipid mediators.
[68] S. Narumiya,et al. Function of prostanoid receptors: studies on knockout mice. , 2002, Prostaglandins & other lipid mediators.
[69] Z. Ungvari,et al. Aging-Induced Phenotypic Changes and Oxidative Stress Impair Coronary Arteriolar Function , 2002, Circulation research.
[70] C. Patrono,et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[71] K. Schrör,et al. Flow cytometry analysis of platelet cyclooxygenase‐2 expression: induction of platelet cyclooxygenase‐2 in patients undergoing coronary artery bypass grafting , 2002, British journal of haematology.
[72] T. Grosser,et al. Role of Prostacyclin in the Cardiovascular Response to Thromboxane A2 , 2002, Science.
[73] K. Do,et al. A Dose-finding Study of Aspirin for Chemoprevention Utilizing Rectal Mucosal Prostaglandin E2 Levels as a Biomarker , 2002 .
[74] S. Narumiya,et al. Roles of Prostaglandin I2 and Thromboxane A2 in Cardiac Ischemia-Reperfusion Injury: A Study Using Mice Lacking Their Respective Receptors , 2001, Circulation.
[75] D. Riendeau,et al. Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits. , 2001, Atherosclerosis.
[76] C. Patrono,et al. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. , 2001, The Journal of clinical investigation.
[77] G. FitzGerald,et al. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[78] D. Fitzgerald,et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. , 2000, Circulation.
[79] H. Claésson,et al. Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries. , 2000, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
[80] A. Livingston. Mechanism of action of nonsteroidal anti-inflammatory drugs. , 2000, The Veterinary clinics of North America. Small animal practice.
[81] I. Meredith,et al. Contribution of vasodilator prostanoids and nitric oxide to resting flow, metabolic vasodilation, and flow-mediated dilation in human coronary circulation. , 1999, Circulation.
[82] G. Harewood. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. , 1999, The New England journal of medicine.
[83] P. Libby,et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. , 1999, The American journal of pathology.
[84] G. FitzGerald,et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. , 1999, The Journal of pharmacology and experimental therapeutics.
[85] R. Hall,et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[86] J. Mitchell,et al. Synergy between cyclo‐oxygenase‐2 induction and arachidonic acid supply in vivo: consequences for nonsteroidal antiinflammatory drug efficacy , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[87] G. FitzGerald,et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[88] P. Lipsky,et al. Cyclooxygenase in biology and disease , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[89] Paul,et al. Distribution of prostaglandin IP and EP receptor subtypes and isoforms in platelets and human umbilical artery smooth muscle cells , 1998, British journal of haematology.
[90] S. Ortiz-Vega,et al. Prostaglandin E2 both stimulates and inhibits adenyl cyclase on platelets: comparison of effects on cloned EP4 and EP3 prostaglandin receptor subtypes. , 1996, Prostaglandins.
[91] P. Hyman-Taylor,et al. Low dose aspirin: selective inhibition of rectal dialysis thromboxane B2 in healthy volunteers , 1994, Alimentary pharmacology & therapeutics.
[92] Walker,et al. Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .
[93] J. Gerrard,et al. The effect of regular and enteric-coated aspirin on bleeding time, thromboxane, and prostacyclin. , 1993, Prostaglandins, leukotrienes, and essential fatty acids.
[94] D. Tsikas,et al. Rapid and selective inhibition of platelet aggregation and thromboxane formation by intravenous low dose aspirin in man. , 1993, Clinical science.
[95] H. Tohgi,et al. Effects of Low‐to‐High Doses of Aspirin on Platelet Aggregability and Metabolites of Thromboxane A2 and Prostacyclin , 1992, Stroke.
[96] T. Hla,et al. Human cyclooxygenase-2 cDNA. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[97] V. Winn,et al. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[98] K. Seibert,et al. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[99] A. Algra,et al. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. , 1991, The New England journal of medicine.
[100] G. FitzGerald,et al. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. , 1991, The New England journal of medicine.
[101] B. Varnum,et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. , 1991, The Journal of biological chemistry.
[102] R. Erikson,et al. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[103] G. Rosen,et al. Identification of a cyclooxygenase-related gene and its potential role in prostaglandin formation. , 1989, Biochemical and biophysical research communications.
[104] J. Ritter,et al. Differential effect of aspirin on thromboxane and prostaglandin biosynthesis in man. , 1989, British journal of clinical pharmacology.
[105] T. Hla,et al. Differential recovery of prostacyclin synthesis in cultured vascular endothelial vs. smooth muscle cells after inactivation of cyclooxygenase with aspirin. , 1989, Prostaglandins, leukotrienes, and essential fatty acids.
[106] H. Eichler,et al. Inhibition of prostacyclin and thromboxane A2 generation by low-dose aspirin at the site of plug formation in man in vivo. , 1987, Circulation.
[107] G. FitzGerald,et al. 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[108] G. FitzGerald,et al. Estimated rate of thromboxane secretion into the circulation of normal humans. , 1986, The Journal of clinical investigation.
[109] J. Ritter,et al. Aspirin causes short-lived inhibition of bradykinin-stimulated prostacyclin production in man , 1985, Nature.
[110] J. Bevan,et al. Inhibition by aspirin of human arterial and venous prostacyclin synthesis. , 1985, Prostaglandins, leukotrienes, and medicine.
[111] G. Davı̀,et al. The Effect of Two Low Doses of Aspirin on Whole Blood Thromboxane and Prostacyclin Generation in Healthy Subjects , 1983, Thrombosis and Haemostasis.
[112] B. Weksler,et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. , 1983, The New England journal of medicine.
[113] G. FitzGerald,et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. , 1983, The Journal of clinical investigation.
[114] M. Greaves,et al. Low-dose aspirin inhibits platelet and venous cyclo-oxygenase in man. , 1982, Thrombosis research.
[115] E. J. Brown,et al. Coronary vasoconstrictor effect of indomethacin in patients with coronary-artery disease. , 1981, The New England journal of medicine.
[116] J. Oates,et al. Estimated rate of prostacyclin secretion into the circulation of normal man. , 1981, The Journal of clinical investigation.
[117] S. Heptinstall,et al. DIFFERENTIAL INHIBITION BY LOW-DOSE ASPIRIN OF HUMAN VENOUS PROSTACYCLIN SYNTHESIS AND PLATELET THROMBOXANE SYNTHESIS , 1981, The Lancet.
[118] C. Stoddard,et al. Inhibition of prostacyclin and platelet thromboxane A2 after low-dose aspirin. , 1981, The New England journal of medicine.
[119] J. M. Bailey,et al. Aspirin: an unexpected side effect on prostacyclin synthesis in cultured vascular smooth muscle cells. , 1980, Science.
[120] A. Marcus,et al. Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. , 1980, The Journal of clinical investigation.
[121] E. Jaffe,et al. Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin. , 1979, The Journal of clinical investigation.
[122] Fraser Dw. Letter: Whooping-cough vaccination. , 1976, British medical journal.
[123] J. Vane,et al. Inhibition of prostaglandin biosynthesis. , 1974, Biochemical pharmacology.
[124] S. Werns. Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes , 2011 .
[125] Xiu-ren Gao,et al. Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome. , 2009, The Journal of pharmacy and pharmacology.
[126] D. Hajjar,et al. Maintaining equilibrium by selective targeting of cyclooxygenase pathways: promising offensives against vascular injury. , 2008, Hypertension.
[127] B. Hinz,et al. Antipyretic analgesics: nonsteroidal antiinflammatory drugs, selective COX-2 inhibitors, paracetamol and pyrazolinones. , 2007, Handbook of experimental pharmacology.
[128] A. Maree,et al. Aspirin and clopidogrel resistance. , 2007, Hematology. American Society of Hematology. Education Program.
[129] E. Antman,et al. Scientific Statement From the American Heart Association Use of Nonsteroidal Antiinflammatory Drugs : An Update for Clinicians: A , 2007 .
[130] J. Mitchell,et al. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs , 2006, Nature Reviews Drug Discovery.
[131] S. Hernández-Díaz,et al. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications , 2006, BMC Medicine.
[132] O. Vesterqvist. Rapid recovery of in vivo prostacyclin formation after inhibition by aspirin , 2004, European Journal of Clinical Pharmacology.
[133] S. Narumiya,et al. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. , 2004, The Journal of clinical investigation.
[134] K. Do,et al. A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[135] S A Rich,et al. The coxibs, selective inhibitors of cyclooxygenase-2. , 2001, The New England journal of medicine.
[136] J. Vane,et al. Cyclooxygenases 1 and 2. , 1998, Annual review of pharmacology and toxicology.
[137] R. Murphy,et al. Current approaches to estimation of eicosanoid formation in vivo. , 1994, Advances in prostaglandin, thromboxane, and leukotriene research.
[138] Fitzgerald Ga,et al. Current approaches to estimation of eicosanoid formation in vivo. , 1994 .
[139] S. Taback,et al. In vivo measurement of thromboxane B2 and 6-keto-prostaglandin F1 alpha in humans in response to a standardized vascular injury and the influence of aspirin. , 1989, Circulation.
[140] G. FitzGerald,et al. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. , 1987, Blood.
[141] T. Hla,et al. Restoration of prostacyclin synthase in vascular smooth muscle cells after aspirin treatment: regulation by epidermal growth factor. , 1985, Journal of lipid research.
[142] K. Salata,et al. Regeneration of prostacyclin synthetase activity in cultured vascular cells following aspirin treatment. , 1980, Advances in prostaglandin and thromboxane research.